The group was founded on March 31, 2010, with a $100 million capital commitment,[1] by Bill Maris who also became GV's first CEO.[9][10][11] In 2012, that commitment was raised to $300 million annually, and the fund has $2 billion under management.[12] In 2014, the group announced $125 million to invest in promising European startups.[13][14] By 2014, it had invested in companies such as Shape Security.[15] In December 2015, the company was renamed GV and introduced a new logo.[16]
As of 2016, GV has been less active as a seed investor, instead shifting its attention to more mature companies.[17][18] There is also a focus on startups in the healthcare markets. It created the biotech company Calico and has invested in Foundation Medicine, Genomics Medicine Ireland, Editas Midicine, and Flatiron Health, among others.[19] In 2020, GV hired Candice Morgan as the firm's first Diversity & Inclusion Partner[20] and promoted Terri Burns from principal to the firm’s first black female partner.[21]
Structure
In 2013, GV developed an intensive, five-day design process, called a Design Sprint, which helps startups solve problems quickly.[22][23][better source needed] It is based on key ideas of agile development and design thinking.[24] In addition, GV provides portfolio companies with access to operational help after making a financial investment.[25] Full-time partners at GV work with portfolio companies on design and product management, marketing, engineering, and recruiting.[26]
^Traitler, Helmut; Coleman, Birgit; Burbidge, Adam (2016). Food Industry R&D: A New Approach. Chichester: John Wiley & Sons. p. 188. ISBN978-1-119-08939-1.
^Hilbush, Brian S. (2021). In Silico Dreams: How Artificial Intelligence and Biotechnology Will Create the Medicines of the Future. Hoboken, NJ: John Wiley & Sons. ISBN978-1-119-74563-1.
